Therefore, in patients with EGFR p.T790M-positive metastatic NSCLC experiencing progression after first-line treatment, osimertinib as an irreversible EGFR-TKI can achieve an objective response rate of over 70% (31). The gene discussed is EGFR; the disease is non-small cell lung carcinoma.